Literature DB >> 29900041

Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells.

Pei Xiao1,2, Xinxin Long3, Lijie Zhang1,2, Yingnan Ye1, Jincheng Guo4, Pengpeng Liu1, Rui Zhang1, Junya Ning1,2, Wenwen Yu2, Feng Wei2, Jinpu Yu1,2.   

Abstract

We previously demonstrated that neurotensin (NTS) induces local inflammation and promotes tumor invasion in hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms are not clear. In this study, positive correlations between NTS and interleukin (IL)-8 were identified at both the mRNA and protein levels in 71 fresh HCC tissues and 100 paraffin-embedded HCC tissues. Furthermore, significant correlations were determined among the co-expression of NTS and IL-8, infiltration of inflammatory cells and enhanced epithelial-mesenchymal transition (EMT) of HCC cells. NTS-induced IL-8 production was associated with activation of the mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) pathways rather than the protein kinase C (PKC) and phosphoinositide-3 kinase (PI3K) pathways, whose specific antagonists significantly inhibited activation of the NTS/IL-8 pathway. IL-8, which promoted EMT and HCC invasion both in vitro and in vivo, was produced by NTS-induced HCC cells and was effectively attenuated by blocking IL-8 receptors in vitro. Moreover, HCC-derived IL-8 attracted more CD68+ tumor-associated macrophages (TAMs) and CD66b+ polymorphonuclear neutrophils (PMNs) to the local microenvironment, displaying enhanced cytokine secretion and phagocytosis. IL-8 stimulated the M2 polarization of TAMs, which promoted the EMT and invasive potential of HCC cells. Blockage of the IL-8 receptor, NTR1 receptor or both significantly reduced HCC metastases in tumor-bearing mouse models via inhibiting EMT. In summary, aberrant activation of the NTS/IL-8 pathway in HCC dramatically stimulated the invasive potential of HCC cells. HCC-derived IL-8 promoted a pro-oncogenic inflammatory microenvironment by inducing M2-type TAMs and indirectly promoting EMT, which might be a valuable therapeutic target to prevent tumor progression.

Entities:  

Keywords:  Neurotensin; epithelial-mesenchymal transition; hepatocellular carcinoma; interleukin-8; tumor-associated macrophages

Year:  2018        PMID: 29900041      PMCID: PMC5993481          DOI: 10.1080/2162402X.2018.1440166

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  54 in total

1.  p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis.

Authors:  M Warny; A C Keates; S Keates; I Castagliuolo; J K Zacks; S Aboudola; A Qamar; C Pothoulakis; J T LaMont; C P Kelly
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Effects of NT on gastrointestinal motility and secretion, and role in intestinal inflammation.

Authors:  Dezheng Zhao; Charalabos Pothoulakis
Journal:  Peptides       Date:  2006-07-26       Impact factor: 3.750

3.  A morphological and immunocytochemical study of a distinctive variant of ductal carcinoma in-situ of the breast.

Authors:  A S Cross; J G Azzopardi; T Krausz; S van Noorden; J M Polak
Journal:  Histopathology       Date:  1985-01       Impact factor: 5.087

4.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells.

Authors:  Romaine I Fernando; Marianne D Castillo; Mary Litzinger; Duane H Hamilton; Claudia Palena
Journal:  Cancer Res       Date:  2011-06-08       Impact factor: 12.701

Review 5.  Chemokines in cancer related inflammation.

Authors:  Paola Allavena; Giovanni Germano; Federica Marchesi; Alberto Mantovani
Journal:  Exp Cell Res       Date:  2010-12-04       Impact factor: 3.905

6.  Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.

Authors:  E K Rofstad; E F Halsør
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

Review 7.  Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.

Authors:  Diego O Croci; Mariano F Zacarías Fluck; María J Rico; Pablo Matar; Gabriel A Rabinovich; O Graciela Scharovsky
Journal:  Cancer Immunol Immunother       Date:  2007-06-15       Impact factor: 6.968

8.  p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells.

Authors:  Yi-Hsien Hsieh; Trang-Tiau Wu; Chih-Yang Huang; Yih-Shou Hsieh; Jin-Ming Hwang; Jer-Yuh Liu
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

Review 9.  Involvement of substance P and the NK-1 receptor in human pathology.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  Amino Acids       Date:  2014-04-06       Impact factor: 3.520

10.  NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma.

Authors:  Yingnan Ye; Xinxin Long; Lijie Zhang; Jieying Chen; Pengpeng Liu; Hui Li; Feng Wei; Wenwen Yu; Xiubao Ren; Jinpu Yu
Journal:  Oncotarget       Date:  2016-10-25
View more
  32 in total

1.  lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression.

Authors:  Mingyan Huang; Huamin Wang; Xiang Hu; Xuetao Cao
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

2.  Effects of G-Rh2 on mast cell-mediated anaphylaxis via AKT-Nrf2/NF-κB and MAPK-Nrf2/NF-κB pathways.

Authors:  Chang Xu; Liangchang Li; Chongyang Wang; Jingzhi Jiang; Li Li; Lianhua Zhu; Shan Jin; Zhehu Jin; Jung Joon Lee; Guanhao Li; Guanghai Yan
Journal:  J Ginseng Res       Date:  2021-10-13       Impact factor: 5.735

3.  Co-culturing polarized M2 Thp-1-derived macrophages enhance stemness of lung adenocarcinoma A549 cells.

Authors:  Xiaocheng Zhang; Mingyang Zhu; Zipu Hong; Chengshui Chen
Journal:  Ann Transl Med       Date:  2021-04

Review 4.  Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.

Authors:  Terence Kin-Wah Lee; Xin-Yuan Guan; Stephanie Ma
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-09       Impact factor: 46.802

5.  Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness.

Authors:  Junya Ning; Yingnan Ye; Dechao Bu; Gang Zhao; Tianqiang Song; Pengpeng Liu; Wenwen Yu; Hailong Wang; Hui Li; Xiubao Ren; Guoguang Ying; Yi Zhao; Jinpu Yu
Journal:  Mol Ther       Date:  2021-02-15       Impact factor: 12.910

Review 6.  Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.

Authors:  Pil Soo Sung
Journal:  Clin Mol Hepatol       Date:  2021-10-19

7.  SIRT1 inhibits hepatocellular carcinoma metastasis by promoting M1 macrophage polarization via NF-κB pathway.

Authors:  Bei Zhou; Yun Yang; Cuiping Li
Journal:  Onco Targets Ther       Date:  2019-04-04       Impact factor: 4.147

8.  Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.

Authors:  Eric J Norris; Qing Zhang; Wendell D Jones; Darla DeStephanis; Ashley P Sutker; Chad A Livasy; Ram N Ganapathi; David L Tait; Mahrukh K Ganapathi
Journal:  J Pathol       Date:  2019-05-14       Impact factor: 7.996

Review 9.  Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.

Authors:  Kristen Fousek; Lucas A Horn; Claudia Palena
Journal:  Pharmacol Ther       Date:  2020-09-24       Impact factor: 12.310

10.  The Inhibitory Effect of Lysophosphatidylcholine on Proangiogenesis of Human CD34+ Cells Derived Endothelial Progenitor Cells.

Authors:  Haijun Zhao; Yanhui He
Journal:  Front Mol Biosci       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.